Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 10, 2025 16:05 ET | Source: Avadel Pharmaceuticals plc DUBLIN, April…
LA28 event programme marks strong commitment towards innovation and gender equality
09 April 2025 - The event programme and athlete quotas for the Olympic…
IOC Executive Board approves signing of French Alps 2030 Olympic Host Contract
09 April 2025 – The International Olympic Committee (IOC) Executive Board (EB),…
DOSIsoft PLANET Onco Dose receives CE MDR Mark and new FDA 510(k) clearance
PARIS, April 7, 2025 /PRNewswire/ -- DOSIsoft, leading provider of patient-specific imaging and…
ENHERTU Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority…
Seemant Shukla Appointed as CEO of Quantum AMC
MUMBAI, India, April 3, 2025 /PRNewswire/ -- The Board of Directors of…
FDA approves Novartis radioligand therapy Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples…
Boxing to be part of LA28 sports programme
20 March 2025 – Boxing will be included on the sports programme…
Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first…
Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is…